Thursday, June 15, 2017

Adamis Obtains FDA Approval for Epinephrine Treatment

Adamis Pharmaceuticals said federal regulators have given it a green light to produce Symjepi, an emergency injection treatment for allergic reactions, providing a potential competitor to Mylan NV’s EpiPen.

from WSJ.com: US Business http://ift.tt/2suuXlP
via IFTTT

No comments:

Post a Comment